The UC Davis/NIH NeuroMab Facility:
- is an NIH-funded national monoclonal antibody-generating resource.
- uses a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs).
- performs comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain in our initial screening procedure.
- optimizes NeuroMabs for use in brain for immunocytochemical-based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
- has made more than 320 NeuroMabs against neuronal membrane proteins (receptors/channels/transporters), synaptic proteins, other neuronal signaling molecules, and proteins with established links to disease states, neurodevelopmental targets, epigenetics targets and rare disease targets.
- makes NeuroMabs available to the neuroscience research community on an inexpensive, non-profit basis as tissue culture supernatants or purified immunoglobulin.
Complete Catalog available online and as a CSV file for download
Custom Antibody Services
- Because we are fully NIH funded, there is no charge for this service.
- Requestors should supply the UC Davis/NIH NeuroMab Facility with:
- a scientific justification as to the biological importance of the target molecule
- the importance of these reagents to the national neuroscience community
- the availability and suitability of existing polyclonal and/or monoclonal antibodies.
- a list of reagents (synthetic peptides, fusions proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) that will be made available to the UC Davis/NIH NeuroMab Facility staff to facilitate the development and characterization of these NeuroMabs.
- Requests will be prioritized by our Scientific Advisory Board and NIH Program Officials.
- Submit suggestions for potential NeuroMab targets here.